2. Search Result
Search Result
Isoforms Recommended: KDM1/LSD1
Results for "

LSD-1

" in MedChemExpress (MCE) Product Catalog:

88

Inhibitors & Agonists

1

Natural
Products

1

Recombinant Proteins

2

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147697
    LSD1-IN-21

    		Histone Demethylase TNF Receptor Inflammation/Immunology Cancer
    LSD1-IN-21 (compound 5a) is a potent and BBB-penetrated LSD1 (Lysine specific demethylase-1) inhibitor, with an IC50 of 0.956 µM. LSD1-IN-21 significantly reduces the pro-inflammatory cytokine TNF-α. LSD1-IN-21 shows good anticancer and anti-inflammatory activity [1].
    <em>LSD1</em>-IN-21
  • HY-152032
    LSD1-IN-23

    		Histone Demethylase Cancer
    LSD1-IN-23 is a competitive/non-competitive mixed inhibitor of lysine specific demethylase 1 (LSD1). LSD1-IN-23 has LSD1 inhibitory activity with an IC50 value of 0.58 μM. LSD1-IN-23 can be used for the research of neuroblastoma (NB) [1].
    <em>LSD1</em>-IN-23
  • HY-144756
    LSD1-IN-15

    		Histone Demethylase Monoamine Oxidase Cancer
    LSD1-IN-15 (compound 1b) is a potent LSD1 inhibitor. LSD1-IN-15 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC50 values of 0.149, 0.028, and 0.327 μM, respectively. LSD1-IN-15 displays cell growth arrest in prostate cancer LNCaP cells, with an IC50 of 9.9 μM [1].
    <em>LSD1</em>-IN-15
  • HY-144757
    LSD1-IN-16

    		Histone Demethylase Monoamine Oxidase Cancer
    LSD1-IN-16 (compound 4b) is a potent LSD1 inhibitor. LSD1-IN-16 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC50 values of 0.015, 0.024, and 0.366 μM, respectively. LSD1-IN-16 displays cell growth arrest in prostate cancer LNCaP cells, with an IC50 of 15.2 μM [1].
    <em>LSD1</em>-IN-16
  • HY-144758
    LSD1-IN-17

    		Histone Demethylase Monoamine Oxidase Cancer
    LSD1-IN-17 (compound 5b) is a potent LSD1 inhibitor. LSD1-IN-17 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC50 values of 0.005, 0.028, and 0.820 μM, respectively. LSD1-IN-17 displays cell growth arrest in prostate cancer LNCaP cells, with an IC50 of 17.2 μM [1].
    <em>LSD1</em>-IN-17
  • HY-155115
    LSD1-IN-27

    		Histone Demethylase PD-1/PD-L1 Cancer
    LSD1-IN-27 (Compound 5ac) is a LSD1 inhibitor (IC50: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer [1].
    <em>LSD1</em>-IN-27
  • HY-149978
    LSD1-IN-26

    		Histone Demethylase Monoamine Oxidase Apoptosis Bcl-2 Family IAP Caspase Cancer
    LSD1-IN-26 (compound 12u) is a potent LSD1 inhibitor, with an IC50 of 25.3 nM. LSD1-IN-26 also inhibits MAO-A (IC50=1234.57 nM) and MAO-B (IC50=3819.27 nM). LSD1-IN-26 significantly induces apoptosis in MGC-803 cells. LSD1-IN-26 can be used for gastric cancer research [1].
    <em>LSD1</em>-IN-26
  • HY-100859
    LSD1-IN-5

    LSD1-IN-5 (Compound 4e) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC50 of 121 nM. LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1 [1].
    <em>LSD1</em>-IN-5
  • HY-100860
    LSD1-IN-6

    		Histone Demethylase Cancer
    LSD1-IN-6 (Compound 4m) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC50 of 123 nM. LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1 [1].
    <em>LSD1</em>-IN-6
  • HY-144675
    LSD1-IN-13

    		Histone Demethylase Cancer
    LSD1-IN-13 (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC50 of 24.43 nM. LSD1-IN-13 can activate CD86 expression, with an EC50 of 470 nM. LSD1-IN-13 induces differentiation of AML (acute myeloid leukemia) cell lines [1].
    <em>LSD1</em>-IN-13
  • HY-144675A
    LSD1-IN-13 hydrochloride

    		Histone Demethylase Cancer
    LSD1-IN-13 hydrochloride (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC50 of 24.43 nM. LSD1-IN-13 hydrochloride can activate CD86 expression, with an EC50 of 470 nM. LSD1-IN-13 hydrochloride induces differentiation of AML (acute myeloid leukemia) cell lines [1].
    <em>LSD1</em>-IN-13 hydrochloride
  • HY-151191
    LSD1-IN-22

    		Histone Demethylase Cancer
    LSD1-IN-22 is a potent Lysine-specific demethylase 1 (LSD1) inhibitor with a Ki value of 98 nM. LSD1-IN-22 has anti-proliferative activity against certain cancer cells [1].
    <em>LSD1</em>-IN-22
  • HY-149968
    LSD1-IN-25

    		Histone Demethylase Apoptosis Cancer
    LSD1-IN-25 (Compound 9j) is a potent, selective and orally active LSD1 inhibitor with an IC50 of 46 nM (Ki = 30.3 nM). LSD1-IN-25 induces cancer cell apoptosis [1].
    <em>LSD1</em>-IN-25
  • HY-160183
    LSD1-IN-29

    		Histone Demethylase Cancer
    LSD1-IN-29 (compound 6) is a Lysine specific demethylase 1 (LSD1) inhibitor with the IC50 of 19 nM [1].
    <em>LSD1</em>-IN-29
  • HY-145861
    LSD1-IN-14

    		Histone Demethylase Apoptosis Cancer
    LSD1-IN-14 is a potent and selective LSD1 inhibitor (IC50=0.89 μM). LSD1-IN-14 can significantly inhibit the proliferation of A549 and THP-1 cells and induce the apoptosis of tumor cells [1].
    <em>LSD1</em>-IN-14
  • HY-151192
    LSD1/2-IN-3

    		Histone Demethylase Cancer
    LSD1/2-IN-3 is a selective inhibitor of lysine-specific demethylase 1 (LSD1), with a Ki value of 11 nM instead of 7 μM for LSD2. There is aberrant expression of LSD1 in cancer stem cells, LSD1/2-IN-1 inhibits LSD1 cell proliferation [1].
    <em>LSD1</em>/2-IN-3
  • HY-144673
    LSD1-IN-12

    		Histone Demethylase Monoamine Oxidase Cancer
    LSD1-IN-12 (compound 2) is a potent LSD1 inhibitor, with Ki values of 1.1 μM (LSD1), 61 μM (LSD2), 2.3 μM (MAO-A), and 3.5 μM (MAO-B), respectively [1].
    <em>LSD1</em>-IN-12
  • HY-149213
    LSD1-IN-24

    		Histone Demethylase PD-1/PD-L1 Cancer
    LSD1-IN-24(compound 3S) is a selective LSD1 inhibitor with IC50 = 0.247 μM. LSD1-IN-24 can mediate the expression of PD-L1, enhance T cell killing response, and can be used in cancer research [1].
    <em>LSD1</em>-IN-24
  • HY-146440
    LSD1/ER-IN-1

    		Histone Demethylase Estrogen Receptor/ERR Apoptosis Cancer
    LSD1/ER-IN-1 (compound 11g) is a potent ER and LSD1 inhibitor, with an IC50 of 1.55 μM (LSD1). LSD1/ER-IN-1 has high affinity selectivity for ERα protein, with α/β ratio of 7.11. LSD1/ER-IN-1 shows good antiproliferative activity against MCF-7 breast cancer cells, with an IC50 of 8.79 μM [1].
    <em>LSD1</em>/ER-IN-<em>1</em>
  • HY-160191
    LSD1-IN-30

    		Histone Demethylase Cancer
    LSD1-IN-30 (compound 3) is a potent inhibitor of lysine-specific demethylase 1 (LSD1), with the IC50 value of 0.291 μM [1].
    <em>LSD1</em>-IN-30
  • HY-149595
    LSD1-UM-109

    		Histone Demethylase Cancer
    LSD1-UM-109 is a ighly potent and reversible LSD1 inhibitor with an IC50 of 3.1 nM. LSD1-UM-109 inhibits cell growth with IC50 values of 0.6 nM in the MV4;11 acute leukemia cell line and 1.1 nM in the H1417 small-cell lung cancer cell line [1].
    <em>LSD1</em>-UM-109
  • HY-146285
    LSD1-IN-20

    		Histone Demethylase Histone Methyltransferase Cancer
    LSD1-IN-20 (compound 1) is a potent dual non-covalent LSD1/G9a inhibitor, with Ki values of 0.44 and 0.68 μM, respectively. LSD1-IN-20 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC50 (72 h) of 0.51 and 1.60 μM, respectively [1].
    <em>LSD1</em>-IN-20
  • HY-151194
    LSD1/2-IN-4

    		Histone Demethylase Cancer
    LSD1/2-IN-4, a PCPA derivative, is an inhibitor of lysine-specific demethylase 1 (LSD1) and lysine-specific demethylase 2 (LSD2). LSD1/2-IN-4 inhibits LSD1 and LSD2 with Ki values of 0.11 μM and 130 μM, respectively. LSD1/2-IN-4 can be used for the research of several cancers including T-cell acute lymphoblastic leukemia (TALL) [1].
    <em>LSD1</em>/2-IN-4
  • HY-146283
    LSD1-IN-18

    		Histone Demethylase Cancer
    LSD1-IN-18 (compound 7) is a potent, non-covalent and selective LSD1 inhibitor, with Ki of 0.156 μM and KD of 0.075 μM, respectively. LSD1-IN-18 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC50 (72 h) of 0.16 and 0.21 μM, respectively [1].
    <em>LSD1</em>-IN-18
  • HY-146284
    LSD1-IN-19

    		Histone Demethylase Cancer
    LSD1-IN-19 (compound 29) is a potent, non-covalent and selective LSD1 inhibitor, with Ki of 0.108 μM and KD of 0.068 μM, respectively. LSD1-IN-19 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC50 (72 h) of 0.17 and 0.40 μM, respectively [1].
    <em>LSD1</em>-IN-19
  • HY-131970
    LSD1/HDAC6-IN-1

    		Histone Demethylase HDAC Cancer
    LSD1/HDAC6-IN-1 is an orally active dual inhibitor of lysine specific demethylase 1(LSD1)/Histone deacetylase 6 (HDAC6), with anti-tumor activity. LSD1/HDAC6-IN-1 can be used for the research of multiple myeloma (MM) [1].
    <em>LSD1</em>/HDAC6-IN-<em>1</em>
  • HY-129388A
    Pulrodemstat

    CC-90011; LSD1-IN-7

    		 Histone Demethylase Cancer
    Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. Pulrodemstat induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity [1].
    Pulrodemstat
  • HY-129388B
    Pulrodemstat benzenesulfonate
    2 Publications Verification

    CC-90011 benzenesulfonate; LSD1-IN-7 benzenesulfonate

    		 Histone Demethylase Cancer
    CC-90011 benzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. CC-90011 benzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 benzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity [1].
    Pulrodemstat benzenesulfonate
  • HY-129388
    Pulrodemstat Methylbenzenesulfonate

    CC-90011 Methylbenzenesulfonate; LSD1-IN-7 Methylbenzenesulfonate

    		 Histone Demethylase Cancer
    CC-90011 Methylbenzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. CC-90011 Methylbenzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 Methylbenzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity [1].
    Pulrodemstat Methylbenzenesulfonate
  • HY-100546
    GSK-LSD1

    GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis [1] .
    GSK-<em>LSD1</em>
  • HY-100546A
    GSK-LSD1 dihydrochloride
    5 Publications Verification

    		 Histone Demethylase Monoamine Oxidase Cancer
    GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC50 of 16 nM.
    GSK-<em>LSD1</em> dihydrochloride
  • HY-12645
    NCL1

    		Histone Demethylase Cancer
    NCL1 is a phenylcyclopropylamine (PCPA)-based Lysine-specific demethylase 1 (LSD1) inhibitor. NCL1 selectively inhibits LSD1 in preference to LSD2, with IC50 values of 2.5 and 26 μM for LSD1 and LSD2, respectively [1].
    NCL<em>1</em>
  • HY-112304
    NCD38 TFA

    		Histone Demethylase Others
    NCD38 TFA is a LSD1-selective inhibitor [1] .
    NCD38 TFA
  • HY-111048
    Corin
    1 Publications Verification

    		 Histone Demethylase HDAC Cancer
    Corin is a dual inhibitor of histone lysine specific demethylase (LSD1) and histone deacetylase (HDAC), with a Ki(inact) of 110 nM for LSD1 and an IC50 of 147 nM for HDAC1.
    Corin
  • HY-146380
    S1427

    		Histone Demethylase Cancer
    S1427 is a tranylcypromine-derived LSD1 inhibitor with the IC50 of 390 nM and Ki of 80 nM. S1427 exhibits desirable hERG channel inhibition and microsomal stability profiles. Inhibition of LSD1 partially reduces the proliferation of cancer cells [1].
    S1427
  • HY-112623
    Vafidemstat
    1 Publications Verification

    ORY-2001

    		 Histone Demethylase Monoamine Oxidase Neurological Disease
    Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor [1].
    Vafidemstat
  • HY-17447A
    Tranylcypromine hydrochloride
    4 Publications Verification

    SKF 385 hydrochloride
    Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression [1] .
    Tranylcypromine hydrochloride
  • HY-15774A
    CBB1003 hydrochloride

    		Histone Demethylase Cancer
    CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.
    CBB1003 hydrochloride
  • HY-15774
    CBB1003

    		Histone Demethylase Cancer
    CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.
    CBB1003
  • HY-18632A
    GSK2879552 dihydrochloride
    Maximum Cited Publications
    10 Publications Verification

    		 Histone Demethylase Cancer
    GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity [1] .
    GSK2879552 dihydrochloride
  • HY-115747
    Namoline

    		Histone Demethylase Cancer
    Namoline, a γ-pyrone, is a selective and reversible Lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 51 μM in a HRP-coupled enzymatic assay. Namoline impairs LSD1 demethylase activity and blocks cell proliferation. Namoline has the potential for androgen-dependent prostate cancer research [1].
    Namoline
  • HY-110130
    RN-1 dihydrochloride

    		Histone Demethylase Cardiovascular Disease Cancer
    RN-1 dihydrochloride is a potent, brain-penetrant, irreversible and selective lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 70 nM. RN-1 dihydrochloride exhibits selectivity for LSD1 over MAO-A and MAO-B with IC50 values of 0.51 μM and 2.785 μM respectively [1] .
    RN-<em>1</em> dihydrochloride
  • HY-112304A
    (1R,2S)-NCD38 TFA

    		Histone Demethylase Others
    (1R,2S)-NCD38 TFA is an enantiomer of NCD38 TFA. NCD38 TFA is a LSD1-selective inhibitor [1] .
    (<em>1</em>R,2S)-NCD38 TFA
  • HY-12635
    SP2509
    5+ Cited Publications

    		 Histone Demethylase Apoptosis Cancer
    SP2509 is a potent and selective antagonist of lysine specific demethylase 1 (LSD1) with an IC50 of 13 nM [1].
    SP2509
  • HY-103085
    T-3775440 hydrochloride
    2 Publications Verification

    		 Histone Demethylase Cancer
    T-3775440 (hydrochloride) is an irreversible lysine-specific histone demethylase (LSD1) inhibitor with an IC50 value of 2.1 nM.
    T-3775440 hydrochloride
  • HY-117226A
    GSK 690 Hydrochloride
    1 Publications Verification

    		 Histone Demethylase Others
    GSK 690 (Hydrochloride) is a reversible inhibitor of lysine specific demethylase 1 (LSD1), with a Kd value of 9 nM and a biochemical IC50 of 37 nM.
    GSK 690 Hydrochloride
  • HY-117226
    GSK 690

    		Histone Demethylase Cancer
    GSK 690 is a reversible inhibitor of lysine specific demethylase 1 (LSD1), with a Kd value of 9 nM and a biochemical IC50 of 37 nM.
    GSK 690
  • HY-151190
    cis-4-Br-2,5-F2-PCPA

    S1024

    		 Histone Demethylase Cancer
    cis-4-Br-2,5-F2-PCPA (S1024) is a selective inhibitor of lysine-specific demethylase 1 (LSD1), with a Ki value of 94 nM instead of 8.4 μM for LSD2. There is aberrant expression of LSD1 in cancer stem cells, cis-4-Br-2,5-F2-PCPA inhibits LSD1 cell proliferation and by increasing the level of dimethylated histone H3 at K4 (H3K4) in CCRF-CEM cells [1].
    cis-4-Br-2,5-F2-PCPA
  • HY-17447AS
    (1S,2R)-Tranylcypromine-d5 hydrochloride

    (1S,2R)-SKF 385-d5 hydrochloride

    		 Monoamine Oxidase Neurological Disease
    (1S,2R)-Tranylcypromine-d5 (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].
    (<em>1</em>S,2R)-Tranylcypromine-d5 hydrochloride
  • HY-12782T
    Iadademstat dihydrochloride
    3 Publications Verification

    ORY-1001 dihydrochloride; RG6016 dihydrochloride; RO 7051790 dihydrochloride

    		 Histone Demethylase Cancer
    Iadademstat (ORY-1001) dihydrochloride is a selective irreversible lysine (K)-specific demethylase 1A (KDM1A/LSD1) inhibitor.
    Iadademstat dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: